2018

Juratli TA, Stasik S, Zolal A, Schuster C, Richter S, Daubner D, Juratli MA, Thowe R, Hennig S, Makina M, Meinhardt M, Lautenschlaeger T, Schackert G, Krex D, Thiede C. TERT Promoter Mutation Detection in Cell-Free Tumor-Derived DNA in Patients with IDH Wild-Type Glioblastomas: A Pilot Prospective Study. Clin Cancer Res. 2018;24:5282-5291.

Krakowsky RHE, Wurm AA, Gerloff D, Katzerke C, Brauer-Hartmann D, Hartmann JU, Wilke F, Thiede C, Muller-Tidow C, Niederwieser D, Behre G. miR-451a abrogates treatment resistance in FLT3-ITD-positive acute myeloid leukemia. Blood Cancer J. 2018;8:36.

Kubasch AS, Wehner R, Bazzurri S, Tunger A, Stasik S, Garzarolli M, Meinel J, Baretton G, Meier F, Thiede C, Schmitz M, Platzbecker U. Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia. Blood Adv. 2018;2:1187-1190.

Middeke JM, Kollinger F, Baldauf H, Stolzel F, Wermke M, von Bonin M, Sockel K, Link CS, Teipel R, Rollig C, Thiede C, Platzbecker U, Ehninger G, Bornhauser M, Schetelig J. Validation of the Revised Pretransplant Assessment of Mortality Score in Patients with Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018;24:1947-1951.

Platzbecker U, Middeke JM, Sockel K, Herbst R, Wolf D, Baldus CD, Oelschlagel U, Mutherig A, Fransecky L, Noppeney R, Bug G, Gotze KS, Kramer A, Bochtler T, Stelljes M, Groth C, Schubert A, Mende M, Stolzel F, Borkmann C, Kubasch AS, von Bonin M, Serve H, Hanel M, Duhrsen U, Schetelig J, Rollig C, Kramer M, Ehninger G, Bornhauser M, Thiede C. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol. 2018;19:1668-1679.

Raffel S, Falcone M, Kneisel N, Hansson J, Wang W, Lutz C, Bullinger L, Poschet G, Nonnenmacher Y, Barnert A, Bahr C, Zeisberger P, Przybylla A, Sohn M, Tonjes M, Erez A, Adler L, Jensen P, Scholl C, Frohling S, Cocciardi S, Wuchter P, Thiede C, Florcken A, Westermann J, Ehninger G, Lichter P, Hiller K, Hell R, Herrmann C, Ho AD, Krijgsveld J, Radlwimmer B, Trumpp A. Author Correction: BCAT1 restricts alphaKG levels in AML stem cells leading to IDH(mut)-like DNA hypermethylation. Nature. 2018;560:E28.

Rollig C, Kramer M, Gabrecht M, Hanel M, Herbst R, Kaiser U, Schmitz N, Kullmer J, Fetscher S, Link H, Mantovani-Loffler L, Krumpelmann U, Neuhaus T, Heits F, Einsele H, Ritter B, Bornhauser M, Schetelig J, Thiede C, Mohr B, Schaich M, Platzbecker U, Schafer-Eckart K, Kramer A, Berdel WE, Serve H, Ehninger G, Schuler US, Study Alliance L. Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients. Ann Oncol. 2018;29:973-978.

Schmidt JR, Rucker-Braun E, Heidrich K, von Bonin M, Stolzel F, Thiede C, Middeke JM, Ehninger G, Bornhauser M, Schetelig J, Schubert K, von Bergen M, Heidenreich F. Pilot Study on Mass Spectrometry-Based Analysis of the Proteome of CD34(+)CD123(+) Progenitor Cells for the Identification of Potential Targets for Immunotherapy in Acute Myeloid Leukemia. Proteomes. 2018;6.

Schuurhuis GJ, Heuser M, Freeman S, Bene MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Dohner K, Roboz GJ, Ossenkoppele GJ. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131:1275-1291.

Stasik S, Schuster C, Ortlepp C, Platzbecker U, Bornhauser M, Schetelig J, Ehninger G, Folprecht G, Thiede C. An optimized targeted Next-Generation Sequencing approach for sensitive detection of single nucleotide variants. Biomol Detect Quantif. 2018;15:6-12.

Suttorp M, Schulze P, Glauche I, Gohring G, von Neuhoff N, Metzler M, Sedlacek P, de Bont E, Balduzzi A, Lausen B, Aleinikova O, Sufliarska S, Henze G, Strauss G, Eggert A, Kremens B, Groll AH, Berthold F, Klein C, Gross-Wieltsch U, Sykora KW, Borkhardt A, Kulozik AE, Schrappe M, Nowasz C, Krumbholz M, Tauer JT, Claviez A, Harbott J, Kreipe HH, Schlegelberger B, Thiede C. Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. Leukemia. 2018.

von Bonin M, Moll K, Kramer M, Oelschlagel U, Wermke M, Rollig C, Thiede C, Ehninger G, Kramer A, Muller-Tidow C, Mitroulis I, Bornhauser M. JAM-C Expression as a Biomarker to Predict Outcome of Patients with Acute Myeloid Leukemia-Letter. Cancer Res. 2018;78:6339-6341.

Crysandt M, Brings K, Beier F, Thiede C, Brummendorf TH, Jost E. Germ line predisposition to myeloid malignancies appearing in adulthood. Expert Rev Hematol. 2018;11:625-636.